Zelira Therapeutics Ltd
ASX:ZLD

Watchlist Manager
Zelira Therapeutics Ltd Logo
Zelira Therapeutics Ltd
ASX:ZLD
Watchlist
Price: 0.39 AUD Market Closed
Market Cap: 4.6m AUD

Operating Margin
Zelira Therapeutics Ltd

-378 242.9%
Current
-56 286.7%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-378 242.9%
=
Operating Profit
-2.6m
/
Revenue
700

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Zelira Therapeutics Ltd
ASX:ZLD
4.6m AUD
-378 243%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
24%
CH
Novartis AG
SIX:NOVN
206.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.5B USD
29%
No Stocks Found

Zelira Therapeutics Ltd
Glance View

Market Cap
4.6m AUD
Industry
Pharmaceuticals

Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The firm's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.

ZLD Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-378 242.9%
=
Operating Profit
-2.6m
/
Revenue
700
What is the Operating Margin of Zelira Therapeutics Ltd?

Based on Zelira Therapeutics Ltd's most recent financial statements, the company has Operating Margin of -378 242.9%.

Back to Top